Endocrine Abstracts

Background: Patients with adrenal insufficiency (AI) require long-term glucocorticoid (GC) replacement therapy and generally show an increased prevalence of bone metabolism alterations. Only few data are available on bone safety of dual-release Hydrocortisone (DR-HC) therapy. Objective: To evaluate bone metabolism in primary AI (PAI) and secondary AI (SAI) during long-term therapy with DR-HC.Methods: We evaluated patients with AI o...